Gotistobart clinical trials
Also written ONC-392 and BNT316.
How each study uses gotistobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the gotistobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
OncoC4, Inc. (5)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test gotistobart, phase 3 first.
- Aug 2027ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsPhase 3 · OncoC4, Inc.
- Nov 2026ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCPhase 1/2 · OncoC4, Inc.
- Dec 2026Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCPhase 1/2 · OncoC4, Inc.
Studies
Open first, then newest update. How each study uses gotistobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Gotistobart Long Term Extension (LTE) StudyEnrolling by invitationPhase 3OncoC4, Inc.NCT07659379Written as Gotistobart
- ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruitingPhase 2OncoC4, Inc.NCT05446298Written as ONC-392
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingPhase 1/2OncoC4, Inc.NCT04140526Written as ONC-392
- ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsActive, not recruitingPhase 3OncoC4, Inc.NCT05671510Written as Gotistobart
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCActive, not recruitingPhase 1/2OncoC4, Inc.NCT05682443Written as ONC-392 low
Given beside what is tested · 1 — gotistobart is usual care or a partner of the new treatment
Codes
What other systems call gotistobart · ClinicalTrials.gg INT014919
- UNII (FDA) 4R46M31XXPGOTISTOBARTOne source FDA
- NCI Thesaurus C173547GotistobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4R46M31XXP | GOTISTOBART | One source FDA |
| NCI Thesaurus | C173547 | Gotistobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.